Ilsung Pharm (003120) — Cash Flow-to-Debt Ratio
Ilsung Pharm (003120) has a Cash Flow-to-Debt Ratio of -0.19x as of December 2025, meaning its operating cash flow of ₩-3.10 Billion could theoretically repay 0% of its total liabilities (₩16.67 Billion) in one year. See 003120 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Ilsung Pharm Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Ilsung Pharm across 13 annual periods. Also explore Ilsung Pharm annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Ilsung Pharm (2013–2025)
Year-by-year debt coverage analysis for Ilsung Pharm. For market capitalisation and broader financial context, see 003120 market cap.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.23x | ₩3.88 Billion | ₩16.67 Billion | ▲ +164.3% |
| 2024 | -0.36x | ₩-4.26 Billion | ₩11.75 Billion | ▲ +68.2% |
| 2023 | -1.14x | ₩-41.47 Billion | ₩36.44 Billion | ▼ -42.7% |
| 2022 | -0.80x | ₩-38.97 Billion | ₩48.85 Billion | ▼ -456.2% |
| 2021 | 0.22x | ₩5.70 Billion | ₩25.47 Billion | ▲ +241.5% |
| 2020 | 0.07x | ₩1.56 Billion | ₩23.75 Billion | ▼ -64.1% |
| 2019 | 0.18x | ₩4.39 Billion | ₩24.03 Billion | ▼ -72.2% |
| 2018 | 0.66x | ₩15.09 Billion | ₩22.93 Billion | ▲ +59.6% |
| 2017 | 0.41x | ₩10.16 Billion | ₩24.64 Billion | ▲ +124.5% |
| 2016 | -1.69x | ₩-31.01 Billion | ₩18.40 Billion | ▼ -1458.3% |
| 2015 | 0.12x | ₩6.04 Billion | ₩48.69 Billion | ▲ +47.1% |
| 2014 | 0.08x | ₩4.19 Billion | ₩49.69 Billion | ▼ -16.9% |
| 2013 | 0.10x | ₩5.06 Billion | ₩49.92 Billion | — |